We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
-4.95%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$130M
AUM Growth
-$1.3M
Cap. Flow
+$5.43M
Cap. Flow %
4.19%
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
2
Reduced
–
Closed
–

Top Buys

1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$5.23M
2
AGRX
Agile Therapeutics
AGRX
+$174K
3
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$25.9K

Top Sells

No sells this quarter

Sector Composition

1 Healthcare 94.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
1
Madrigal Pharmaceuticals
MDGL
$12.8B
$122M 94.25%
854,053
+35,786
+4% +$5.23M
CPXX
2
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$6.65M 5.13%
2,246,469
– –
COV
3
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$593K 0.46%
6,572
+346
+6% +$25.9K
AGRX
4
DELISTED
Agile Therapeutics
AGRX
$217K 0.17%
+12
New +$174K

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q2 2014 Portfolio in Review

As of Q2 2014, Caxton Corporation held 4 positions worth $130M, down 0.99% from $131M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Caxton Corporation deployed $5.43M of net new capital in Q2 2014, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Agile Therapeutics: 12 shares worth $217K.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier.

  • Caxton Corporation's largest Q2 2014 buy was Agile Therapeutics: 12 shares worth $217K.
  • Caxton Corporation added most to Madrigal Pharmaceuticals in Q2 2014, an estimated $5.23M increase.
  • Caxton Corporation's ten largest holdings make up 100% of its $130M portfolio in Q2 2014.
  • Caxton Corporation opened 1 new position and closed 0 in Q2 2014.
  • Caxton Corporation's portfolio value fell 0.99% quarter-over-quarter to $130M.

Based on Caxton Corporation's 13F filing for Q2 2014, filed 14 Aug 2014.